Cover Image
市場調查報告書

Cardio3 BioSciences SA的產品平台分析

Cardio3 BioSciences SA - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 226256
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Cardio3 BioSciences SA的產品平台分析 Cardio3 BioSciences SA - Product Pipeline Review - 2014
出版日期: 2014年06月15日 內容資訊: 英文 23 Pages
簡介

本報告提供Cardio3 BioSciences SA的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Cardio3 BioSciences SA的基本資料

Cardio3 BioSciences SA概要

  • 主要資訊
  • 企業資料

Cardio3 BioSciences SA:R&D概要

  • 主要的治療範圍

Cardio3 BioSciences SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Cardio3 BioSciences SA:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Cardio3 BioSciences SA:藥物簡介

  • C3BSCQR-1
  • C3BSGQR-1
  • C3BSGQR-4

Cardio3 BioSciences SA:開發平台分析

  • 各給藥途徑
  • 各分子類型

Cardio3 BioSciences SA:最近的開發平台趨勢

Cardio3 BioSciences SA:暫停中的計劃

Cardio3 BioSciences SA:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04982CDB

Global Markets Direct's, 'Cardio3 BioSciences SA - Product Pipeline Review - 2014', provides an overview of the Cardio3 BioSciences SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cardio3 BioSciences SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cardio3 BioSciences SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cardio3 BioSciences SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cardio3 BioSciences SA's pipeline products

Reasons to buy

  • Evaluate Cardio3 BioSciences SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cardio3 BioSciences SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cardio3 BioSciences SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cardio3 BioSciences SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cardio3 BioSciences SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cardio3 BioSciences SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cardio3 BioSciences SA Snapshot
    • Cardio3 BioSciences SA Overview
    • Key Information
    • Key Facts
  • Cardio3 BioSciences SA - Research and Development Overview
    • Key Therapeutic Areas
  • Cardio3 BioSciences SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cardio3 BioSciences SA - Pipeline Products Glance
    • Cardio3 BioSciences SA - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Cardio3 BioSciences SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Cardio3 BioSciences SA - Drug Profiles
    • C3BSCQR-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C3BSGQR-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C3BSGQR-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cardio3 BioSciences SA - Pipeline Analysis
    • Cardio3 BioSciences SA - Pipeline Products by Route of Administration
    • Cardio3 BioSciences SA - Pipeline Products by Molecule Type
  • Cardio3 BioSciences SA - Recent Pipeline Updates
  • Cardio3 BioSciences SA - Dormant Projects
  • Cardio3 BioSciences SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cardio3 BioSciences SA, Key Information
  • Cardio3 BioSciences SA, Key Facts
  • Cardio3 BioSciences SA - Pipeline by Indication, 2014
  • Cardio3 BioSciences SA - Pipeline by Stage of Development, 2014
  • Cardio3 BioSciences SA - Monotherapy Products in Pipeline, 2014
  • Cardio3 BioSciences SA - Phase III, 2014
  • Cardio3 BioSciences SA - Preclinical, 2014
  • Cardio3 BioSciences SA - Pipeline by Route of Administration, 2014
  • Cardio3 BioSciences SA - Pipeline by Molecule Type, 2014
  • Cardio3 BioSciences SA - Recent Pipeline Updates, 2014
  • Cardio3 BioSciences SA - Dormant Developmental Projects,2014

List of Figures

  • Cardio3 BioSciences SA - Pipeline by Top 10 Indication, 2014
  • Cardio3 BioSciences SA - Pipeline by Stage of Development, 2014
  • Cardio3 BioSciences SA - Monotherapy Products in Pipeline, 2014
  • Cardio3 BioSciences SA - Pipeline by Top 10 Molecule Type, 2014
Back to Top